1 / 3

WT G>A G>C G>T

oren-henry
Télécharger la présentation

WT G>A G>C G>T

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure S1.Box plot showing pack-years of smoking according to different KRAS mutations substitutions. Median packs-year consumed by patients whose tumors harbored G>T mutations (45) was higher compared to other KRAS mutants (G>A, 30; G>C, 40.5) and wild-type (WT, 30; Kruskal-Wallis p = 0.041). p = 0.041 150 Packs-year 100 50 0 WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

  2. Supplementary Figure S2. Kaplan-Meier plots of disease-free survival (DFS) and overall survival (OS) according to distinct KRAS codon variants. Patients harboring KRAS-G12C mutation had significantly shorter DFS and OS compared to KRAS wild-type or other codon variants of KRAS. (A) Patients harboring KRAS-G12C mutations had significantly worse DFS rate at 2 years (42.9% ± 8.4) as compared to other KRAS mutants (G12A, 75% ± 15.3; G12V, 78.6% ± 11.0; G12D, 53.3% ± 12.9) and wild-type (73.4% ± 4.6). (B) Concordantly, patients with KRAS-G12C mutations had significantly worse OS rate at 2 years (60% ± 8.3) as compared to other mutants (G12A, 87.5% ± 11.7; G12V, 92.9% ± 6.9; G12D, 86.7% ± 8.8) and wild-type (79.6% ± 4.2). Wild-type (n = 94) KRAS G12C (n = 35) KRAS G12D (n = 15) KRAS G12V (n = 14) KRASG12A (n = 8) Wild-type (n = 94) KRAS G12C (n = 35) KRAS G12D (n = 15) KRAS G12V (n = 14) KRASG12A (n = 8) 1.0 1.0 Log-rank test p < 0.001 Log-rank test p = 0.004 0.8 0.8 0.6 0.6 Overall survival (%) Disease-free survival (%) 0.4 0.4 0.2 0.2 0.0 0.0 Log-rank test P < 0.001 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Months after surgery Months after surgery

  3. Supplementary Figure S3. Kaplan-Meier plots of overall survival (OS) according to KRAS codon variant from TCGA-LUAD cohort. Patients with tumors harboring KRAS-G12C had significantly shorter median overall survival (32.9 months) as compared to KRAS-nonG12C (not reached; unadjusted HR = 3.26, CI 95% 1.06-10.04, p = 0.039). Interestingly, KRAS-G12C was significantly associated with worse survival in the multivariate analysis adjusted by stage and adjuvant treatment (HR =10.16, 95% CI 2.19 – 47.11, p = 0.003). 1.0 KRAS-nonG12C (n = 35) 0.8 0.6 Overall survival (%) 0.4 KRAS-G12C (n = 32) 0.2 0.0 HR = 3.26, p = 0.039 0 10 20 30 40 50 60 Months after surgery

More Related